A5085017956- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pleural and Pulmonary Diseases
- Occupational and environmental lung diseases
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Multiple Myeloma Research and Treatments
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Lung Cancer Treatments and Mutations
- Endoplasmic Reticulum Stress and Disease
- Cholangiocarcinoma and Gallbladder Cancer Studies
- vaccines and immunoinformatics approaches
- Polyomavirus and related diseases
- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- Drug-Induced Adverse Reactions
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Herpesvirus Infections and Treatments
- Cancer therapeutics and mechanisms
University of St. Gallen
2021-2022
Kantonsspital St. Gallen
2015-2021
Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not β2 activity of proteasome. Bortezomib-resistant cells down-regulate activation status unfolded protein response, up-regulate proteasome activity. To improve inhibition in bortezomib-resistant to achieve more efficient UPR activation, we have developed LU-102, selective LU-102 inhibited intact at low micromolar concentrations without relevant co-inhibition subunits. In...
Treatment with sotorasib has shown intracranial complete responses and continued stabilization in KRAS G12C-mutated non-small-cell lung carcinoma (NSCLC) patients previously treated, stable brain metastases a post hoc analysis of the ongoing CodeBreaK 100 trial. We present case patient G12C-mutant adenocarcinoma active untreated nearly response only 6 weeks after start illustrating benefit active, NSCLC.
Background: Anti-PD-(L)1 monoclonal antibodies (mAb) have changed the therapeutic landscape in patients with advanced NSCLC, still 35-40% of these derive no benefit from anti-PD-(L)1 mAb. Antibiotics alter gut microbiota diversity and composition, may affects antitumor immune responses following checkpoint inhibitors (ICI) NSCLC. Methods: We retrospectively included 218 NSCLC receiving Overall survival (OS) (primary endpoint), progression free (PFS) radiological response was compared between...
Immune checkpoint inhibitors (ICIs) have improved the survival of patients with non-small cell lung cancer (NSCLC) by reinvigorating tumor-specific T responses. However, specificity such cells and human leukocyte antigen (HLA)-associated epitopes recognized, remain elusive. In this study, we identified NSCLC recently described NSCLC-associated antigens, termed keratinocyte differentiation antigens. Epitopes these antigens were presented HLA-A 03:01 HLA-C 04:01 associated responses to ICI...
Abstract Background Herpes simplex virus (HSV) is commonly associated with oro-facial and genital manifestations. It rarely causes encephalitis even less commonly, in heavily immunosuppressed patients, visceral disease or bronchopneumonitis. We present a case of cytologically-proven, PCR-positive HSV-1 tracheobronchitis pneumonitis patient severe immunocompromise. Case presentation A 64 year old white man steroid-induced diabetes mellitus progressive small-cell bronchial carcinoma despite...